Avéma Pharma Solutions is pleased to be attending CPhI in Philadelphia (May 17-19, Philadelphia Convention Center) at Booth #1315. We look forward to seeing our customers and prospects in person and sharing the exciting new developments at Avé

Avéma Pharma Solutions Ramps Up Capacity, Adding New 135,000-Square-Foot Site in Miami

To support our expanding business in the development and manufacture of oral liquid and solid-dose prescription and OTC drugs, Avéma Pharma Solutions and its parent company, PL Developments, have acquired a new 135,000-square-foot facility in Miami. The new site is earmarked to enable additional R&D development, analytical labs, and will allow future manufacturing growth and warehousing needs for the company’s Florida operations — serving both its CDMO customer base and its private-label offerings. This site is the company’s 10th location in the U.S. and will begin operations in the summer of 2022.

Full CDMO Capabilities

As a fully-integrated CDMO, Avéma offers its contract customers services that range from R&D development to pilot-scale manufacturing to commercial manufacturing and bottling. Avéma’s commitment to design of experiment (DoE) techniques can help reduce FDA review time for new product submissions. This streamlined approach helps companies accelerate R&D and efficiently transfer to commercial production quickly and cost-effectively, cutting weeks out of traditional timelines.

Avéma Pharma Solutions has more than 33 years of Rx formulation development experience and offers a wide range of product capabilities, including small-volume pilot-scale production capabilities, high-potency compounds and small molecule drug development, as well as designing drug delivery systems, such as:

• Immediate release systems.
• Modified release systems.
• Delayed-release and extended-release.
• Chewable tablets, quick dissolve tablets, two-piece hard-shell capsules and taste masking.

As a wholly-owned subsidiary of PL Developments, one of the largest private label companies in the U.S, Avéma leverages the resources and expertise of both companies to help customers bring products to market quickly, efficiently, and cost-effectively. The advantages of working with Avéma and PLD include:

• The knowledge and experience to develop your product from concept through commercialization.
• Large portfolio of commercialized formulations that includes 80 ANDAs.
• Broad range of in-house APIs, excipients, and packaging materials to increase your speed-to-market.
• All products developed and manufactured at U.S.-based locations.
• Over 1 million square feet of cGMP-compliant manufacturing and research facilities.

About Avéma Pharma Solutions

Avéma Pharma Solutions is a division of PL Developments — a leading manufacturer, packager, and distributor of over-the-counter (OTC) pharmaceutical products and consumer health care goods. Avéma Pharma Solutions offers complete, turnkey product development and manufacturing solutions at Miami facility, including R&D, product development, validation, testing, demonstration batches, small-scale manufacturing, and transfer to commercial levels.